Gritstone bio, Inc.
gritstonebio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2024 10-Q, filed Aug 13, 2024. Its latest SEC filing is a 4 from Apr 8, 2025.
10-Q for Q2 FY2024, filed Aug 13, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops vaccine-based immunotherapy candidates for cancer and infectious diseases, including personalized and off-the-shelf cancer vaccines and vaccines targeting viral diseases.
10-K for FY2023, filed Mar 5, 2024We are a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to…View ↗
In oncology, we develop vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their…View ↗
In infectious disease, we develop therapeutic and prophylactic vaccines targeting both T cells and B cells. We believe we are leading the…View ↗
How Did They Make Money?
Grant providers fund research as qualifying research costs arise. Collaboration and license partners may pay upfront fees, payments tied to development, regulatory and commercial milestones, manufacturing-service fees, and royalties on licensed products.
10-K for FY2023, filed Mar 5, 2024
-
10-K for FY2023, filed Mar 5, 2024
FY2023 revenue by product or service ↗
$16.3M
-
10-K for FY2023, filed Mar 5, 2024
$16.3M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaboration and license revenues
|
8.1%
FY2020: 86%
|
Collaboration and license revenues, FY2023
$1.3M Sources
|
|
|
Grant revenues
Recurring
10-K for FY2023, filed Mar 5, 2024 |
92%
FY2020: 14%
|
Grant revenues, FY2023
$15M Sources
|
Recurring |
Who Were Their Customers?
Research funders and pharmaceutical partners support vaccine development through grants, contracts and collaborations; named counterparts include Gilead, CEPI, the Gates Foundation and the Biomedical Advanced Research and Development Authority.
10-K for FY2023, filed Mar 5, 2024Continue advancing the CORAL program and conduct research and development on additional pathogens/infectious diseases. We believe the novel…View ↗
Our clinical programs include GRANITE, an individualized neoantigen-based vaccine program; SLATE, an “off-the-shelf” neoantigen-based…View ↗
To date, we have not generated any revenue from product sales and we do not expect to generate any revenue from product sales for the…View ↗
Revenue RecognitionView ↗
Did Revenues Turn Into Profits?
No. It lost $138.5M in FY2023.
10-K for FY2023, filed Mar 5, 2024
−$139.6MView ↗
10-K for FY2023, filed Mar 5, 2024
−$138.5MView ↗
10-K for FY2023, filed Mar 5, 2024
−$126.2MView ↗
How Were They Changing?
10-Q for Q2 FY2024, filed Aug 13, 2024
Open tableView ↗
-
Apr 4, 2025
Bankruptcy reorganization took effect and canceled the old common shares
The company emerged as the reorganized debtor; holders of canceled equity interests received no property under the plan.
Sources
8-K, filed Apr 4, 2025
On April 3, 2025, the Court entered an order (the “Confirmation Order”) confirming the Second Modified Plan of Reorganization of Gritstone…View ↗
-
Jan 3, 2025
Sold substantially all assets and its CEO resigned
The asset sale closed, and Andrew Allen resigned as president and CEO effective the next day.
Sources
8-K, filed Jan 3, 2025
In connection with the Chapter 11 Case, on December 30, 2024, the Company entered into an asset purchase agreement (the “APA”) with Seattle…View ↗
-
Oct 16, 2024
Nasdaq determined the common stock would be delisted
The company did not intend to appeal the determination.
Sources
8-K, filed Oct 16, 2024
On October 11, 2024, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq…View ↗
-
Oct 10, 2024
Filed for Chapter 11 bankruptcy protection
The company filed a voluntary petition and began a Chapter 11 case.
Sources
8-K, filed Oct 10, 2024
On October 10, 2024 (the “Petition Date”), Gritstone bio, Inc. (the “Company”) filed a voluntary petition for relief under chapter 11 of…View ↗
Grew. Revenue grew 3.7x in 4 years, from $4.4M in FY2019 to $16.3M in FY2023, about 39% a year.
More manufacturing moved in-house
The older report described in-house facilities as part of vaccine manufacturing. The latest says the company moved most manufacturing steps that had been outsourced in-house.
10-K for FY2020, filed Mar 11, 2021 10-K for FY2023, filed Mar 5, 2024The second pillar of our tumor-specific cancer immunotherapy approach is our potent antigen delivery system, which delivers TSNA to…View ↗
Since we commenced operations in August 2015, we have invested a significant portion of our efforts and financial resources in research and…View ↗
Who Did They Compete With?
Competes with BioNTech, Genentech, Moderna Therapeutics, Merck, Achilles Therapeutics, Astrazeneca, Evaxion Biotech, NousCom, Nykode Therapeutics, Transgene, Geneos Therapeutics, Pfizer, Johnson & Johnson, Novavax, Sanofi, GlaxoSmithKline, Arcturus Therapeutics, CureVac, Replicate Bioscience, and HDT Bio
10-K for FY2023, filed Mar 5, 2024In the neoantigen space, BioNTech AG in collaboration with Genentech Inc., Moderna Therapeutics, Inc. in collaboration with Merck & Co.…View ↗
Loading...
